CN117337182A - 一种水通道蛋白抑制剂的药物组合物及其制备方法 - Google Patents

一种水通道蛋白抑制剂的药物组合物及其制备方法 Download PDF

Info

Publication number
CN117337182A
CN117337182A CN202180057413.1A CN202180057413A CN117337182A CN 117337182 A CN117337182 A CN 117337182A CN 202180057413 A CN202180057413 A CN 202180057413A CN 117337182 A CN117337182 A CN 117337182A
Authority
CN
China
Prior art keywords
pharmaceutical composition
trifluoromethyl
bis
phenyl
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180057413.1A
Other languages
English (en)
Chinese (zh)
Inventor
钱勇
史瑞文
刘佳雯
宋田
刘艳红
冯爱娟
任晋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Simcere Pharmaceutical Co Ltd
Aeromics Inc
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd, Aeromics Inc filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Publication of CN117337182A publication Critical patent/CN117337182A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180057413.1A 2020-08-05 2021-08-04 一种水通道蛋白抑制剂的药物组合物及其制备方法 Pending CN117337182A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010779964 2020-08-05
PCT/CN2021/110506 WO2022028459A1 (en) 2020-08-05 2021-08-04 Pharmaceutical composition of aquaporin inhibitor and preparation method thereof

Publications (1)

Publication Number Publication Date
CN117337182A true CN117337182A (zh) 2024-01-02

Family

ID=80120008

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180057413.1A Pending CN117337182A (zh) 2020-08-05 2021-08-04 一种水通道蛋白抑制剂的药物组合物及其制备方法

Country Status (12)

Country Link
US (1) US20230293556A1 (https=)
EP (1) EP4192442A4 (https=)
JP (1) JP2023536509A (https=)
KR (1) KR20230137284A (https=)
CN (1) CN117337182A (https=)
AU (1) AU2021323181A1 (https=)
BR (1) BR112023002129A2 (https=)
CA (1) CA3187716A1 (https=)
IL (1) IL300341A (https=)
MX (1) MX2023001493A (https=)
TW (1) TW202228714A (https=)
WO (1) WO2022028459A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024208207A1 (zh) * 2023-04-03 2024-10-10 拜西欧斯（北京）生物技术有限公司 一种双取代萘化合物及其药物组合物和用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
US20160279155A1 (en) 2013-11-06 2016-09-29 Aeromics, Inc. Novel formulations
US11117909B2 (en) 2016-05-13 2021-09-14 Aeromics, Inc. Crystals
WO2025075479A1 (ko) * 2023-10-04 2025-04-10 이화여자대학교 산학협력단 아쿠아포린 4 억제제의 심방세동 치료 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163506A (zh) * 2013-11-06 2016-11-23 埃罗米克斯公司 新配方

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488363C (en) * 2002-06-06 2011-01-04 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
WO2008067196A2 (en) * 2006-11-16 2008-06-05 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
WO2013169939A2 (en) * 2012-05-08 2013-11-14 Aeromics, Llc New methods
CA2931550C (en) * 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US11117909B2 (en) * 2016-05-13 2021-09-14 Aeromics, Inc. Crystals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163506A (zh) * 2013-11-06 2016-11-23 埃罗米克斯公司 新配方

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024208207A1 (zh) * 2023-04-03 2024-10-10 拜西欧斯（北京）生物技术有限公司 一种双取代萘化合物及其药物组合物和用途

Also Published As

Publication number Publication date
JP2023536509A (ja) 2023-08-25
AU2021323181A1 (en) 2023-03-23
IL300341A (en) 2023-04-01
MX2023001493A (es) 2023-06-23
EP4192442A1 (en) 2023-06-14
BR112023002129A2 (pt) 2023-04-18
US20230293556A1 (en) 2023-09-21
TW202228714A (zh) 2022-08-01
CA3187716A1 (en) 2022-02-10
EP4192442A4 (en) 2025-03-19
KR20230137284A (ko) 2023-10-04
WO2022028459A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CN117337182A (zh) 一种水通道蛋白抑制剂的药物组合物及其制备方法
KR100824554B1 (ko) 주사제로 유용한 피페라실린 및 타조박탐을 함유하는조성물
AU2007322334B2 (en) Method of drug delivery for bone anabolic protein
EP2822591B1 (en) Pharmaceutical formulations of tnf-alpha antibodies
EP2676677A1 (en) Highly concentrated anti-cd40 antibody pharmaceutical preparation
WO2014041425A1 (en) Daptomycin formulations and uses thereof
JP2018531268A (ja) ダントロレンを含む水性組成物
JP2018531268A6 (ja) ダントロレンを含む水性組成物
KR20010034240A (ko) 약학 조성물
CN117320727A (zh) 低吸附格列本脲制剂及方法
JP5750680B2 (ja) ５α−アンドロスタン−３β，５，６β−トリオール注射剤及びその調製方法
RU2007152C1 (ru) Офтальмологическое средство и способ его получения
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
CN102688183B (zh) 一种稳定的盐酸莫西沙星注射剂
KR100725076B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물 함유 용액 및 제제
KR20230008148A (ko) 눈의 상황을 치료하기 위한 제제
EP4223295B1 (en) Liquid pharmaceutical composition demonstrating excellent preservation efficacy
KR20060002795A (ko) 엔도톡신-관련 질병 및 질환의 예방 및 치료용 조성물 및방법
WO2017198224A1 (zh) 一种瑞马唑仑的药物组合物
EA024344B1 (ru) Составы для инфузии лантибиотиков типа b
CN115969781A (zh) 一种枸橼酸爱地那非注射剂及其制备方法和用途
CN120154577B (zh) 一种注射用伏立康唑冻干粉针及其制备方法
RU2014050C1 (ru) Офтальмологическое средство и способ его получения
CN109078001A (zh) 一种新型万古霉素纳米脂质体组合物及其制备方法
EP4342453A1 (en) Eye drop composition for treating dry eye syndrome containing recoflavone and method for preparing same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination